A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma.
Ju WT, Xia RH, Zhu DW, Dou SJ, Zhu GP, Dong MJ, Wang LZ, Sun Q, Zhao TC, Zhou ZH, Liang SY, Huang YY, Tang Y, Wu SC, Xia J, Chen SQ, Bai YZ, Li J, Zhu Q, Zhong LP.
Ju WT, et al. Among authors: sun q.
Nat Commun. 2022 Sep 14;13(1):5378. doi: 10.1038/s41467-022-33080-8.
Nat Commun. 2022.
PMID: 36104359
Free PMC article.
Clinical Trial.